AUROBAC THERAPEUTICS
- Biotech or pharma, therapeutic R&D
As a biopharma founded in 2022 by Boehringer Ingelheim, Evotec and bioMérieux, AUROBAC ambitions to become a global leader in the fight against bacterial infections, Antimicrobial Resistance (AMR) and their consequences in acute hospital settings.